Reasons For Admission In Patients With Cancer, Leukemia, Lymphoma, And Multiple Myeloma (Rap-Calm) At Moi Teaching And Referral Hospital: Eldoret, Kenya-A Pilot Study.

e18676 Background: In this study, we describe the distribution of hospital admissions for patients with cancer, including malignant solid tumors, leukemia, and lymphoma, in a tertiary referral center in Eldoret, Kenya. A consultation to Hematology/Oncology is placed for patients with an active diagnosis of cancer who are admitted to MTRH. Methods: We followed patients with an active diagnosis of cancer (solid malignant tumor, multiple myeloma, leukemia, or lymphoma) who were admitted to MTRH over the five months extending between September 2017 and January 2018. Medical information was extracted from the weekly inpatient consult service summaries. Results: Table 1 shows the patient characteristics. Median length of stay was 17 days (range: 1 – 439 days) for our 157 patients. Females had a significantly longer length of stay when compared to males (38 versus 18 days, p = 0.043). 24.3% of patients died during the hospital stay. Four patients were readmitted during the study interval. 80.5% of patients with solid tumors had stage IV disease. Most patients (13.1%) were admitted to the hospital with symptomatic anemia requiring transfusion therapy. Other reasons for admission are detailed in Table 1. Conclusions: Despite recent advances, length of hospital stays, cancer stage at the time of presentation, and inpatient mortality rates remain high. Table 1. Characteristics of patients admitted to Moi Teaching and Referral Hospital in Eldoret, Kenya Sex, % female 90 (57.3%) Age, median in years (range) 48 years (14 – 48 years) Cancer diagnosis, % Breast 36 (22.9%) Sarcoma (angiosarcoma, rhabdomyosarcoma, synovial sarcoma, osteosarcoma) 10 (6.4%) Multiple myeloma 9 (5.7%) Acute myeloid leukemia 9 (5.7%) Colorectal 9 (5.7%) Non-Hodgkin’s lymphoma 9 (5.7%) Chronic myelogenous leukemia 8 (5.1%) Hepatocellular carcinoma 7 (4.5%) Reasons for admission Anemia requiring transfusion therapy 21 (13.1%) Respiratory failure 20 (12.5%) Breast infection 14 (8.8%) Refractory pain 10 (6.3%) Poor feeding, vomiting, hypovolemia 9 (5.6%) Stage of cancer for solid malignant tumors, % Stage I 0 Stage II 2 (1.6%) Stage III 22 (17.9%) Stage IV 99 (80.5%)